Beranda › Sindrom Mielodisplastik › North Carolina › Durham
Uji klinis Sindrom Mielodisplastik di Durham, NC
14 studi untuk Sindrom Mielodisplastik mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Menerima pesertaFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Menerima pesertaFase 3
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Menerima pesertaFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Menerima pesertaFase 1/2
- Duke Cancer Institute, Durham
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Menerima pesertaFase 1/2
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi jauhnya
Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Menerima pesertaFase 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Menerima pesertaFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi jauhnya
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Menerima pesertaFase 1
- Duke Cancer Center, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauhnya
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Uji klinis Sindrom Mielodisplastik di kota lain
- Houston, TX43 studi
- Baldwin Park, CA26 studi
- New York City, NY21 studi
- Seattle, WA21 studi
- Washington, DC20 studi
- Tampa, FL19 studi
- Boston, MA19 studi
- Miami, FL17 studi
- Columbus, OH14 studi
- St. Louis, MO13 studi
- Atlanta, GA13 studi
- Chicago, IL13 studi
Studi lain di Durham
- Kanker Payudara64 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Leukemia Mieloid Akut33 studi
- Kanker Metastatik33 studi
- Kanker Prostat32 studi
- Kanker Paru32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Leukemia Limfositik Kronis27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.